NTLANEUTRAL

Gross Margin

85.4%

Higher than 85% of Healthcare sector peers

Updated 1078h ago

Sector Performance

85th percentile

NTLA

85.4%

Sector Median

68.9%

Sector Avg

-20.2%

📊

Deep Analysis

Intellia Therapeutics, Inc. (NTLA) has a Gross Margin of 85.4% as of May 2026.

This places NTLA in the 85th percentile of the Healthcare sector, which has a median Gross Margin of 68.9% and a sector average of -20.2%. NTLA's Gross Margin is 23.9% above the sector median. In context: Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

Frequently Asked Questions

What does the Gross Margin tell investors about NTLA?

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

How is the Gross Margin calculated?

Gross Margin is calculated as: Gross Profit / Revenue.

How does NTLA's Gross Margin compare to its sector?

NTLA's Gross Margin of 85.4% compares to a Healthcare sector median of 68.9%, placing it in the 85th percentile.

Who are NTLA's closest peers by Gross Margin?

The closest Healthcare peers by Gross Margin include: AMGN (68.2%), TDOC (67.8%), TECH (66.9%), NTRA (64.8%), RMD (62.2%).

The Formula

Gross Profit / Revenue

Why It Matters

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.